Nirsevimab Respiratory Syncytial Virus monoclonal antibody: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice
The primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention Program recommendation) in Queensland, Australia.
The study will focus on:
1\. Assessing the immunisation rates among eligible infants (born from 1 February 2024 to 15 April 2025) in their first Respiratory Syncytial Virus (RSV)-season in Queensland.
Secondary objectives of this study are as follows:
1. To analyse reasons of parents to decide for or against immunisation of their infant with nirsevimab.
1. This objective aims to assess potential influencing factors and evaluate the changes in acceptance across the three cohorts prior and post recommendation.
2. In this regard, demographic factors (e.g. education, income) will be included in the analysis where applicable to gain insights on their potential impact.
2. To assess immunisation rates for further subgroups, e.g. by: a) risk group (defined chronic condition or pre-term birth status), b) regional areas of Queensland.
3. To compare the vaccination coverage rate estimates with data captured via the Australian Immunisation Register.
| Facility | City | Region | Status |
|---|---|---|---|
| Paratus Clinical Research | Brisbane | Queensland | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07615192 on ClinicalTrials.gov ↗ ← All trials in Australia